// App-Quantinova.ai

2878 : Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Researchers

Presenter

  • Jayakumar Vadakekolathu

Principal Investigators

  • Sarah E. Church

  • Michael P. Rettig

  • Ibrahim Aldoss

  • Geoffrey L Uy

  • Norbert Vey

  • Ashkan Emadi

  • Peter H. Sayre

  • Roland B. Walter

  • Matthew C Foster

  • Martha L. Arellano

  • John E. Godwin

  • Matthew J. Wieduwilt

  • Michael T. Byrne

  • Laura C. Michaelis

  • Patrick J. Stiff

  • Matteo Giovanni Carrabba

  • Patrice Chevalier

  • Emmanuel Gyan

  • Christian Recher

  • Anjali S Advani

  • Martin Wermke

  • Harry P. Erba

  • Fabio Ciceri

  • Geert Huls

  • Mojca Jongen-Lavrencic

  • Farhad Ravandi

  • Antonio Curti

  • Max S. Topp

  • John Muth

  • Patrick Kaminker

  • Bob Lowenberg

  • Ivana Gojo

  • Leo Luznik

  • John F. DiPersio

  • Jan K Davidson-Moncada

  • Sergio Rutella

Medical Centers

  • John van Geest Cancer Research Centre,Nottingham Trent University,Nottingham,United Kingdom

  • NanoString Technologies, Inc., Seattle, WA

  • Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO.

  • University of Southern California, CA

  • BMT and Leukemia Program, Washington University School of Medicine, Saint Louis, MO

  • Service -Hematologie Clinique, Institut Paoli Calmettes, Marseille, France

  • University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC), Baltimore, MD

  • University of California, San Francisco, San Francisco, CA

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC

  • Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA

  • Providence Medical Center, Portland, OR

  • Moores Cancer Center, University of California, San Diego, La Jolla, CA

  • Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN

  • Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

  • Loyola University Chicago Stritch School of Medicine, Maywood, IL

  • Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy

  • Department of Hematology and Cell Therapy, CHU Nantes, Nantes, France

  • CHU de Tours - Hôpital Bretonneau, Tours, France

  • Service d'Hématologie,Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole,TOULOUSE,France

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • NCT/UCC Early Clinical Trial Unit, Universitätsklinikum Carl Gustav Carus, Dresden, Germany

  • Duke University College of Medicine, Durham, NC

  • Pathology Unit, San Raffaele H. Scientific Institute, Milano, Italy

  • Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Hematology/Oncology "L. e A. Seràgnoli", Sant’Orsola-Malpighi University Hospital, Bologna, Bologna, Italy

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

  • MacroGenics, Inc., Rockville, MD

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Centre for Health, Ageing and Understanding Disease (CHAUD), Nottingham Trent University, Nottingham, United Kingdom

Locations

  • United Kingdom

  • United States

  • France

  • Italy

  • Germany

  • Netherlands

Companies

  • MacroGenics, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 38

  • Cluster of Differentiation 4

  • Cluster of differentiation 45

  • Cluster of differentiation 69

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

  • Cytotoxic T-lymphocyte-associated protein 4

  • Human Leukocyte Antigen – DR isotype

  • Interferon-gamma

  • Interleukin 1 alpha

  • T-cell receptor

  • T helper 2

  • Type 1 T helper

Drug/Treatment

  • Flotetuzumab

  • Interferon

  • IFN-lambda

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • NCT02152956

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved